REPORT ID 4473

United States Inactivated Vaccine Market Report 2019

Publish Date
2019
Pages
99
Format
Electronic (PDF)

In this report, the United States Inactivated Vaccine market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Inactivated Vaccine in these regions, from   2019 to 2025 (forecast).

United States Inactivated Vaccine market competition by top manufacturers/players, with Inactivated Vaccine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Astellas Pharma (Japan)
    CSL Limited (Australia)
    Emergent BioSolutions (U.S.)
    GlaxoSmithKline (U.K.)
    Johnson & Johnson (U.S.)
    MedImmune (U.S.)
    Merck & Co (U.S.)
    Pfizer (U.S.)
    Sanofi Pasteur (France)
    Serum Institute of India Pvt (India)

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    By End User
        Pediatrics
        Adults
    By Disease Indication
        Pneumococcal
        Influenza
        HPV
        Hepatitis
        Rotavirus
        DTP
        Polio
        MMR
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Medical Center
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Inactivated Vaccine Market  Report 2019
1 Inactivated Vaccine Overview
    1.1 Product Overview and Scope of Inactivated Vaccine
    1.2 Classification of Inactivated Vaccine by Product Category
        1.2.1 United States Inactivated Vaccine Market Size (Sales Volume) Comparison by Type ( 2014-2024)
        1.2.2 United States Inactivated Vaccine Market Size (Sales Volume) Market Share by Type (Product Category)  in 2018
        1.2.3 Pediatrics
        1.2.4 Adults
    1.3 United States Inactivated Vaccine Market by Application/End Users
        1.3.1 United States Inactivated Vaccine Market Size (Consumption) and Market Share Comparison by Application ( 2014-2024)
        1.3.2 Hospital
        1.3.3 Medical Center
        1.3.4 Others
    1.4 United States Inactivated Vaccine Market by Region
        1.4.1 United States Inactivated Vaccine Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 The West Inactivated Vaccine Status and Prospect ( 2014-2024)
        1.4.3 Southwest Inactivated Vaccine Status and Prospect ( 2014-2024)
        1.4.4 The Middle Atlantic Inactivated Vaccine Status and Prospect ( 2014-2024)
        1.4.5 New England Inactivated Vaccine Status and Prospect ( 2014-2024)
        1.4.6 The South Inactivated Vaccine Status and Prospect ( 2014-2024)
        1.4.7 The Midwest Inactivated Vaccine Status and Prospect ( 2014-2024)
    1.5 United States Market Size (Value and Volume) of Inactivated Vaccine ( 2014-2024)
        1.5.1 United States Inactivated Vaccine Sales and Growth Rate ( 2014-2024)
        1.5.2 United States Inactivated Vaccine Revenue and Growth Rate ( 2014-2024)

2 United States Inactivated Vaccine Market Competition by Players/Suppliers
    2.1 United States Inactivated Vaccine Sales and Market Share of Key Players/Suppliers ( 2014-2019)
    2.2 United States Inactivated Vaccine Revenue and Share by Players/Suppliers ( 2014-2019)
    2.3 United States Inactivated Vaccine Average Price by Players/Suppliers ( 2014-2019)
    2.4 United States Inactivated Vaccine Market Competitive Situation and Trends
        2.4.1 United States Inactivated Vaccine Market Concentration Rate
        2.4.2 United States Inactivated Vaccine Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Inactivated Vaccine Manufacturing Base Distribution, Sales Area, Product Type

3 United States Inactivated Vaccine Sales (Volume) and Revenue (Value) by Region ( 2014-2019)
    3.1 United States Inactivated Vaccine Sales and Market Share by Region ( 2014-2019)
    3.2 United States Inactivated Vaccine Revenue and Market Share by Region ( 2014-2019)
    3.3 United States Inactivated Vaccine Price by Region ( 2014-2019)

4 United States Inactivated Vaccine Sales (Volume) and Revenue (Value) by Type (Product Category) ( 2014-2019)
    4.1 United States Inactivated Vaccine Sales and Market Share by Type (Product Category) ( 2014-2019)
    4.2 United States Inactivated Vaccine Revenue and Market Share by Type ( 2014-2019)
    4.3 United States Inactivated Vaccine Price by Type ( 2014-2019)
    4.4 United States Inactivated Vaccine Sales Growth Rate by Type ( 2014-2019)

5 United States Inactivated Vaccine Sales (Volume) by Application ( 2014-2019)
    5.1 United States Inactivated Vaccine Sales and Market Share by Application ( 2014-2019)
    5.2 United States Inactivated Vaccine Sales Growth Rate by Application ( 2014-2019)
    5.3 Market Drivers and Opportunities

6  United States Inactivated Vaccine Players/Suppliers Profiles and Sales Data
    6.1 Astellas Pharma (Japan)
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Inactivated Vaccine Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Astellas Pharma (Japan) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 CSL Limited (Australia)
        6.2.2 Inactivated Vaccine Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 CSL Limited (Australia) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 Emergent BioSolutions (U.S.)
        6.3.2 Inactivated Vaccine Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Emergent BioSolutions (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 GlaxoSmithKline (U.K.)
        6.4.2 Inactivated Vaccine Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 GlaxoSmithKline (U.K.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 Johnson & Johnson (U.S.)
        6.5.2 Inactivated Vaccine Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Johnson & Johnson (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 MedImmune (U.S.)
        6.6.2 Inactivated Vaccine Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 MedImmune (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 Merck & Co (U.S.)
        6.7.2 Inactivated Vaccine Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Merck & Co (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 Pfizer (U.S.)
        6.8.2 Inactivated Vaccine Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Pfizer (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview
    6.9 Sanofi Pasteur (France)
        6.9.2 Inactivated Vaccine Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Sanofi Pasteur (France) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.9.4 Main Business/Business Overview
    6.10 Serum Institute of India Pvt (India)
        6.10.2 Inactivated Vaccine Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Serum Institute of India Pvt (India) Inactivated Vaccine Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.10.4 Main Business/Business Overview

7 Inactivated Vaccine Manufacturing Cost Analysis
    7.1 Inactivated Vaccine Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Inactivated Vaccine

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Inactivated Vaccine Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Inactivated Vaccine Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Inactivated Vaccine Market Size (Value and Volume) Forecast ( 2019-2025)
    11.1 United States Inactivated Vaccine Sales Volume, Revenue Forecast ( 2019-2025)
    11.2 United States Inactivated Vaccine Sales Volume Forecast by Type ( 2019-2025)
    11.3 United States Inactivated Vaccine Sales Volume Forecast by Application ( 2019-2025)
    11.4 United States Inactivated Vaccine Sales Volume Forecast by Region ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer